Study of the amino acid composition of thermoacid coagulation fractions of probiotic products

The developed mathematical model allows good prediction of the quantity of heat saved based on applied technological parameters. The process of distribution of amino acids between whey and protein clot was studied during thermoacid coagulation of milk fermented by a consortium of bifidobacteria Lactococcus lactis subsp. diacetilactis, Streptococcus thermophiles, Propionibacterium freudenreichii, Bifidobacterium bifidum with an active cell concentration of 109 CFU/ml. The distribution of amino acids indicates the predominant transition of amino acids of microbial origin into coagulum. An increase in the content of such amino acids as lysine and leucine was found, the concentration of valine, isoleucine, methionine, threonine, phenlalanine, which had a rate of more than 100%, decreased. The predominant transfer of microbial exopolysaccharides - metabolic products of probiotic microorganisms - is noted in serum, which makes it an especially valuable biological resource for the production of eubiotic drinks

Real-world study of efficacy, risk management and reasons for discontinuation of natalizumab for treatment of multiple sclerosis in Russia.

BackgroundNTZ is approved in Russia for the treatment of highly active relapsing remitting multiple sclerosis and is reimbursed via federal budget program. However, no data about NTZ treatment in Russia and the effect of federal reimbursement have been performed so far.ObjectiveTo characterize the population of patients receiving natalizumab and assess the efficacy and risk-management plan (RMP) implementation of NTZ therapy in routine clinical practice in Russia.MethodsWe analyzed data for 334 patients, who received at least one infusion of NTZ. Relapse rate, MRI activity, NEDA-3 status after 2 years were assessed. Anti-JC virus antibodies status and RMP implementation were evaluated. Drop-out rate and reasons for therapy discontinuation were analyzed.ResultsPatients switched to natalizumab in Russia are mainly female (63%), with median EDSS score of 3.5 and high disease activity: 93% had at least 1 relapse and 58% had both T1Gd+ and new T2 lesion a year before therapy initiation. Introduction of federal reimbursement allowed patients with less relapses to start therapy with natalizumab. The only predictor of 6-month progression was EDSS score at the baseline of therapy (HR = 2.1375, 95%CI 1.0026-4.5570, p = 0.0492). 82% patients reached NEDA-3 at 24 month of therapy. 25% of patients discontinued NTZ for reasons: tolerability (14.5%), JCV antibody status (61%), and patient's decision (17%). RMP was implemented in only 36% patients.ConclusionNatalizumab appeared to have high efficacy in Russian clinical practice. Federal reimbursement allowed less active patients to start natalizumab. More efforts should be done to improve RMP implementation